Valeant Pharmaceuticals International Inactive 10-Q2006 Q3 Quarterly report

Filed: 23 Jan 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: accuracy, actuarial, admitting, advantage, aforementioned, Aliso, allegedly, analyzed, appointed, Ardea, arm, assay, assistance, aware, backdating, Basel, bDNA, belong, boycotted, cancer, ceased, CEO, CFO, Chilean, classification, clear, commenced, composed, conceal, conclusion, contacted, cooperate, cooperated, correct, correction, correctly, cure, default, deficiency, defined, denial, department, detectable, detected, display, distracting, diversify, diversion, documentation, employment, enrichment, expressly, flat, flawed, formulation, gradually, group, guanosine, HCV, heard, highest, hire, illustrate, immaterial, inconclusive, incorrectly, Incremental, incurrence, ineligible, input, inquiry, intensive, investigate, investigated, investigation, IRC, joined, judge, Kenneth, knew, Lawson, lead, left, likelihood, list, lowest, mature, Michael, misstatement, moved, negligible, neuropathic, Notwithstanding, occurrence, officially, optimal, pain, paper, partner, partnering, pattern, point, postretirement, preceding, prolonged, Pronko, properly, publicly, pursuit, questioned, randomized, rank, reacquire, reclassification, reconstructed, regimen, relevant, remote, resale, rescission, RNA, sample, sixteen, slight, steady, stream, strike, summary, surrender, surrendered, theform, TMA, transferee, trustee, undertook, unjust, upfront, Viejo, virologic, week, York, Yugoslavian

Removed: artificially, bear, Bedoyecta, built, carried, channel, compensatory, defending, defense, dispose, false, foregoing, Health, individually, inflating, LLC, multiple, participation, promulgated, recover, remain, Russia, sought, stuffing, supervision, target, thereunder, unsuccessful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Valeant Pharmaceuticals International similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, each of the undersigned officers of Valeant Pharmaceuticals International hereby certifies, to the best of such officer’s knowledge, that:

1. The Registrant’s quarterly report onForm 10-Q for the quarter ended September 30, 2006 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Registrant as of and for the periods presented in the Report.

/s/ Timothy C. Tyson

Timothy C. Tyson

President and Chief Executive Officer

Date: January 22, 2007

/s/ Bary G. Bailey

Bary G. Bailey

Executive Vice President and Chief Financial Officer

Date: January 22, 2007

A signed original of this written statement required by Section 906 has been provided to Valeant Pharmaceuticals International and will be furnished to the Securities and Exchange Commission or its staff upon request.